TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31443102

Group type: EXPERIMENTAL
Intervention: 1.8 × 10^10 CFU B. infantis EVC001 daily for 21 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Breast milk alone (controls)
Number of subjects: 120
Study: 28421383

Group type: EXPERIMENTAL
Intervention: Guanfacine XR 1 mg orally on Day 1, followed by 1 mg (Days 4-8), 2 mg (Days 9-13), 3 mg (Days 14-18), and 4 mg (Days 19-23) once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25966824

Group type: EXPERIMENTAL
Intervention: Individualized, formula-based dosing of Genotropin®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard weight-based dosing of Genotropin®
Number of subjects: 0
Study: 24088130

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing (genetic plus clinical information)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Clinical information only
Number of subjects: 109
Study: 21315341

Group type: EXPERIMENTAL
Intervention: FSH bolus at time of hCG trigger
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 19371312

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (0.2 mg)
Number of subjects: 12
Study: 16877722

Group type: EXPERIMENTAL
Intervention: Chronomodulated infusion of fluorouracil, leucovorin, and oxaliplatin for 4 days (chronoFLO4)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Conventional 2-day delivery of fluorouracil, leucovorin, and oxaliplatin (FOLFOX2)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Chronomodulated infusion (chronoFLO4) in women
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Chronomodulated infusion (chronoFLO4) in men
Number of subjects: 564
Study: 15522472

Group type: EXPERIMENTAL
Intervention: Transcatheter closure of PDA with coils
Number of subjects: 70
Study: 10902785

Group type: EXPERIMENTAL
Intervention: QUICKI (1/[log(I(0)) + log(G(0))])
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 56
Study: 9076577

Group type: EXPERIMENTAL
Intervention: Calcitriol treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Before calcitriol treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Residual values of set point (PTHstim) before calcitriol
Number of subjects: 58

Group type: COMPARATOR
Intervention: Residual values of set point (PTHstim) after calcitriol
Number of subjects: 58
Study: 8222495

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice a day for 2 weeks after 1 week of placebo or indomethacin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice a day for 2 weeks after 1 week of placebo or indomethacin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Indomethacin 50 mg twice a day for 3 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3513075

Group type: EXPERIMENTAL
Intervention: 4-epi-DX + 5-FU
Number of subjects: 62

Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 62
Study: 30047574

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: No catheter ablation (CA)
Number of subjects: 1240
Study: 26784336

Group type: EXPERIMENTAL
Intervention: Water jets installation in schools
Number of subjects: 1065562
Study: 24613404

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound-guided RFVTA
Number of subjects: 135
Study: 22772051

Group type: EXPERIMENTAL
Intervention: Achieve inner lumen mapping catheter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Circular mapping catheter
Number of subjects: 40
Study: 20347564

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LMA CTrach
Number of subjects: 42

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 42
Study: 18672472

Group type: EXPERIMENTAL
Intervention: Fampridine 10 mg twice daily
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Fampridine 15 mg twice daily
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Fampridine 20 mg twice daily
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 15906951

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) (n=139)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: CEE plus 5 mg medroxyprogesterone acetate (MPA) (n=97)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: CEE plus 10 mg MPA (n=109)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group (BMI <25 Kg/m2)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Overweight group (BMI >=25 Kg/m2)
Number of subjects: 345
Study: 12888586

Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg/day for 3 days
Number of subjects: 373

Group type: COMPARATOR
Intervention: Co-amoxiclav 45 mg/kg/day for 10 days
Number of subjects: 373
Study: 11270004

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study: 9753705

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg i.v.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hyoscine N-butylbromide 20 mg i.v.
Number of subjects: 32
Study: 7910470

Group type: EXPERIMENTAL
Intervention: 0.1 mg suriclone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.2 mg suriclone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.4 mg suriclone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg) vs Suriclone (0.4 mg)
Number of subjects: 15
Study: 3111101

Group type: EXPERIMENTAL
Intervention: Low dose dexamethasone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Double doses of dexamethasone
Number of subjects: 16
Study: 30909787

Group type: EXPERIMENTAL
Intervention: Local intra‐arterial prostaglandin therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonintervention
Number of subjects: 32
Study: 31160549

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (Arm 1: 0.2 mg/kg/day, Arm 2: 0.15-0.175 mg/kg/day, Arm 3: 0.2 mg/kg/day delayed until Day 5)
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (early lower-dose and delayed higher-dose regimens)
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (early-lower tacrolimus arm with older donors, delayed higher-dose tacrolimus arm with younger donors)
Number of subjects: 844
Study: 29231428

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with catgut implantation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Catgut implantation
Number of subjects: 120
Study: 25961367

Group type: EXPERIMENTAL
Intervention: Standard treatment according to the diagnostic algorithm
Number of subjects: 441

Group type: COMPARATOR
Intervention: Regular consultation by a doctor
Number of subjects: 441
Study: 23452825

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study: 21392712

Group type: EXPERIMENTAL
Intervention: High-calcium (HC) diet supplying 1,500 mg calcium/d
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual diet (UC)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: High-calcium (HC) diet
Number of subjects: 149
Study: 19106155

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) during target vessel (TV) PCI
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Arm RIPC in patients with single vessel disease
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 54
Study: 17031767

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions (low-frequent, psycho-educative, supportive approaches)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 715
Study: 15172393

Group type: EXPERIMENTAL
Intervention: Bayesian approach to statistical inference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional approach to statistical hypothesis testing
Number of subjects: 0
Study: 10668706

Group type: EXPERIMENTAL
Intervention: Lu25-109 25 mg tid
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Lu25-109 50 mg tid
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Lu25-109 100 mg tid
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study: 9058328

Group type: EXPERIMENTAL
Intervention: 10% doxycycline hyclate (DH)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5% sanguinarium chloride (SC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No agent (VC)
Number of subjects: 180
Study: 8103953

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 171

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 171
Study: 30332285

Group type: EXPERIMENTAL
Intervention: Dixon T1-weighted MRI
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Turbo inversion recovery magnitude MRI
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: WB DWI MRI
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced T1-weighted VIBE MRI
Number of subjects: 58
Study: 27784410

Group type: EXPERIMENTAL
Intervention: Custom-made mandibular repositioning device (MRDc)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ready-made mandibular repositioning device (MRDr)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of MRDc and MRDr
Number of subjects: 25
Study: 25497480

Group type: EXPERIMENTAL
Intervention: Attention/emotion skills and meditation training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 23169319

Group type: EXPERIMENTAL
Intervention: 125 mg SC abatacept weekly
Number of subjects: 646

Group type: COMPARATOR
Intervention: 40 mg SC adalimumab biweekly
Number of subjects: 646
Study: 21494062

Group type: EXPERIMENTAL
Intervention: 16-session disorder-specific SAD treatment program including parent training and classical cognitive-behavioral therapy (CBT) components
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 43
Study: 17882417

Group type: EXPERIMENTAL
Intervention: Dalteparin (5,000 U sub-Q daily)
Number of subjects: 42
Study: 16177271

Group type: EXPERIMENTAL
Intervention: Brief educational module explaining placebos in more depth
Number of subjects: 49

Group type: COMPARATOR
Intervention: Routine explanation of placebos in the context of consent
Number of subjects: 49
Study: 14504565

Group type: EXPERIMENTAL
Intervention: l-tryptophan
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 10873185

Group type: EXPERIMENTAL
Intervention: Graded compression stockings
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 98
Study: 9363277

Group type: EXPERIMENTAL
Intervention: Single breath vital capacity rapid inhalation induction (VCRII)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multiple deep breaths inhalation induction (DBI)
Number of subjects: 40
Study: 1489025

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (n = 11) with background infusion of 4 ml.h-1 of bupivacaine 0.125% with fentanyl 1 microgram.ml-1 and 3-6 ml bolus doses as required (15 min lockout interval)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Continuous infusion epidural analgesia (n = 12) with continuous infusion starting at 10 ml.h-1, adjustable up to 25 ml.h-1
Number of subjects: 23
Study: 2872336

Group type: EXPERIMENTAL
Intervention: Syrup of ipecac 60 ml plus water 480 ml followed by activated charcoal 50 g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Activated charcoal 50 g
Number of subjects: 10
Study: 29749641

Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods
Number of subjects: 31

Group type: COMPARATOR
Intervention: Eucaloric control foods
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 27990505

Group type: EXPERIMENTAL
Intervention: GENESIS Implant System
Number of subjects: 53

Group type: COMPARATOR
Intervention: PRIMA Implant System
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 53
Study: 24928953

Group type: EXPERIMENTAL
Intervention: Endothelin receptor blockade (bosentan)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 19
Study: 21048504

Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153

Group type: COMPARATOR
Intervention: Brinzolamide and Placebo
Number of subjects: 153
Study: 20395894

Group type: EXPERIMENTAL
Intervention: ADMA levels
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SDMA levels
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ADMA/SDMA ratio
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Creatinine, IL-6, and CRP levels in ICU survivors
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ADMA levels in ICU survivors
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SDMA levels in ICU survivors
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ADMA/SDMA ratio in ICU survivors
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Creatinine, IL-6, TNF-alpha, CRP, and ADMA levels in non-survivors
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SDMA levels in non-survivors
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: ADMA/SDMA ratio in non-survivors
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SDMA as a marker
Number of subjects: 72
Study: 17324648

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (age-matched women)
Number of subjects: 158
Study: 15026508

Group type: EXPERIMENTAL
Intervention: Real rTMS (10 Hz) for 20 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study: 11758896

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (Pulmicort Turbuhaler) 800 microg/day for 4 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oral theophylline (Talotren tablets, 200 mg twice daily) for 4 weeks
Number of subjects: 38
Study: 9158315

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (lidocaine with sodium bicarbonate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 30
Study: 7964811

Group type: EXPERIMENTAL
Intervention: Tizanidine 2 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tizanidine 4 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tizanidine 8 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2890671

Group type: EXPERIMENTAL
Intervention: Piquindone (RO22‐1319)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31034014

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: FV diet
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 459
Study: 28553091

Group type: EXPERIMENTAL
Intervention: Peer-led education and mentorship program (n=53)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (n=52)
Number of subjects: 105
Study: 27282118

Group type: EXPERIMENTAL
Intervention: XR‐NTX only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XR‐NTX plus patient navigation (PN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (ETAU)
Number of subjects: 0
Study: 25128802

Group type: EXPERIMENTAL
Intervention: Intranasal FluMist seasonal influenza vaccine (3 doses on Days 0, 28, and 56) + rintatolimod (50 μg, 200 μg, or 500 μg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intranasal FluMist seasonal influenza vaccine + rintatolimod
Number of subjects: 12
Study: 21910949

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) 4 g in juice, consumed twice daily for 3 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo, consumed twice daily for 3 weeks
Number of subjects: 37
Study: 19652172

Group type: EXPERIMENTAL
Intervention: Hand hygiene (136 households)
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Surgical facemasks plus hand hygiene (137 households)
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Lifestyle education (control) (134 households)
Number of subjects: 1201
Study: 17697173

Group type: EXPERIMENTAL
Intervention: Experimental resins (R1, R2, R3, R4, R5) applied to acid-etched dentine saturated with ethanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental resins (R1, R2, R3, R4, R5) applied to acid-etched dentine saturated with water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smear layer-covered dentine
Number of subjects: 0
Study: 16055308

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 500

Group type: COMPARATOR
Intervention: Low dose of Haloperidol
Number of subjects: 500
Study: 12109650

Group type: EXPERIMENTAL
Intervention: High dose Gammalinolenic acid (GLA) extracted from Evening Primrose Oil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High dose Gammalinolenic acid (GLA)
Number of subjects: 90
Study: 10405233

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1.0 g) with Lansoprazole (30 mg) after pretreatment with 30 mg once daily for 2 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Acetaminophen (1.0 g) alone (control session)
Number of subjects: 6
Study: 7486359

Group type: EXPERIMENTAL
Intervention: Prochlorperazine (10 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 2123602

Group type: EXPERIMENTAL
Intervention: Immediate intravenous heparin anticoagulation (5,000 U bolus followed by 1,000 U/hour)
Number of subjects: 84

Group type: COMPARATOR
Intervention: rt‐PA alone
Number of subjects: 84
Study: 7418403

Group type: EXPERIMENTAL
Intervention: Quinesterol (long-acting estrogen)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control (DMPA without quinesterol)
Number of subjects: 214
Study: 31364228

Group type: EXPERIMENTAL
Intervention: OA-enriched olive oil (55 mL/day, equivalent to 30 mg OA/day)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (same oil not enriched)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: OA-enriched olive oil
Number of subjects: 176
Study: 28401134

Group type: EXPERIMENTAL
Intervention: iCCAS
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study: 25869753

Group type: COMPARATOR
Intervention: DDDR (n = 385)
Number of subjects: 1166

Group type: COMPARATOR
Intervention: MVP (n = 398)
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: DDDRP+MVP (n = 383)
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Reactive ATP efficacy
Number of subjects: 1166
Study: 23509827

Group type: EXPERIMENTAL
Intervention: Specific strength training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: General fitness training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Repetitive stressful work
Number of subjects: 28
Study: 21214497

Group type: EXPERIMENTAL
Intervention: Broadband light (400-800 nm) at 180 mW/cm², twice a day for 4 min/session
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo light (10 mW/cm²)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Broadband light (400-800 nm)
Number of subjects: 16
Study: 19957880

Group type: EXPERIMENTAL
Intervention: Response format: true‐false
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response format: agree‐disagree
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response format: yes‐no
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Framing of items around freedom given responsibility
Number of subjects: 0

Group type: COMPARATOR
Intervention: Framing of items around responsibility given freedom
Number of subjects: 0
Study: 17926613

Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy with 'Hongwai Zhike Plaster' at Dazhui (GV 14), Dingchuan (EX‐B 1), Tiantu (CV 22) plus common treatment.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Common treatment (giving up smoking, proper exercise).
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy.
Number of subjects: 300
Study: 15569129

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg b.i.d.)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Metformin (1 g b.i.d.)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 12882461

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9639502

Group type: EXPERIMENTAL
Intervention: Peripheral T-cell lymphomas (PTCL)
Number of subjects: 1883

Group type: COMPARATOR
Intervention: B-cell lymphomas (BCL)
Number of subjects: 1883

Group type: EXPERIMENTAL
Intervention: T-ALCL (anaplastic large cell lymphoma)
Number of subjects: 1883
Study: 8194130

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma from HIV-infected patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV-infected patients
Number of subjects: 0
Study: 2695415

Group type: EXPERIMENTAL
Intervention: Cefaclor, 40 mg/kg/day in 3 divided doses for 10 days
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX), 1 mg/kg/day (trimethoprim 8 mg, sulfamethoxazole 40 mg) in 2 divided doses for 10 days
Number of subjects: 86